Back to School: How biopharma can reboot drug development. Access exclusive analysis here
SNSS restructured and reduced headcount by 35 (25%) to 108 to focus on its clinical programs and extend its financial resources
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury